ERASCA INC
NASDAQ: ERAS (Erasca, Inc.)
Last update: 2 days ago, 8:53PM21.49
-0.98 (-4.36%)
| Previous Close | 22.47 |
| Open | 22.49 |
| Volume | 5,736,513 |
| Avg. Volume (3M) | 5,332,898 |
| Market Cap | 6,679,082,496 |
| Price / Book | 21.47 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Diluted EPS (TTM) | -0.570 |
| Total Debt/Equity (MRQ) | 12.72% |
| Current Ratio (MRQ) | 12.35 |
| Operating Cash Flow (TTM) | -107.72 M |
| Levered Free Cash Flow (TTM) | -91.89 M |
| Return on Assets (TTM) | -22.16% |
| Return on Equity (TTM) | -45.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Erasca, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.75 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.69% |
| % Held by Institutions | 84.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Logos Global Management Lp | 31 Dec 2025 | 13,000,000 |
| Arch Venture Management, Llc | 31 Dec 2025 | 11,055,554 |
| Vivo Capital, Llc | 31 Dec 2025 | 9,273,428 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Clear Street, -6.93%) | Buy |
| Median | 17.50 (-18.57%) | |
| Low | 15.00 (HC Wainwright & Co., -30.20%) | Buy |
| Average | 17.50 (-18.57%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 12.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Clear Street | 06 Mar 2026 | 20.00 (-6.93%) | Buy | 15.47 |
| HC Wainwright & Co. | 26 Jan 2026 | 15.00 (-30.20%) | Buy | 9.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Erasca to Present at Upcoming Conferences in February |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |